Moleculin Biotech (NASDAQ:MBRX) issued its earnings results on Monday. The company reported ($0.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.05), Fidelity Earnings reports.
Shares of MBRX traded up $0.01 during trading hours on Wednesday, hitting $1.22. The stock had a trading volume of 12,520 shares, compared to its average volume of 10,739,746. The company has a market cap of $42.29 million, a PE ratio of -2.38 and a beta of 2.26. Moleculin Biotech has a 1-year low of $0.78 and a 1-year high of $3.15.
MBRX has been the subject of several analyst reports. Zacks Investment Research lowered Moleculin Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 14th. Maxim Group set a $3.00 price objective on Moleculin Biotech and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Finally, ValuEngine lowered Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, January 30th.
TRADEMARK VIOLATION WARNING: “Moleculin Biotech (MBRX) Releases Earnings Results” was originally posted by WKRB News and is the sole property of of WKRB News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.wkrb13.com/2019/05/15/moleculin-biotech-mbrx-releases-earnings-results.html.
Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.
Featured Article: How Do Mutual Funds Work?
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.